- Active not recruitingPHASE3
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
This study is testing a new drug called selpercatinib for a type of thyroid cancer that has spread or can't be removed by surgery. It wants to see if this new drug is safer and works better than current treatments for people with a specific gene change (RET mutation).
For: Medullary Thyroid CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
This study looks at using detailed tumour gene testing to guide treatment for advanced breast cancer. It compares giving targeted drugs based on these tests with standard chemotherapy or immunotherapy for patients whose cancer has responded well to initial treatment.
For: Metastatic Breast CancerFrance